Niiki Pharma Inc.

Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339

Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results

HOBOKEN, New Jersey and PHILADELPHIA, September 20, 2011 - Niiki Pharma Inc.

Older News

HOBOKEN, New Jersey and PHILADELPHIA, June 1, 2011 - - Phase I Data for NKP-1339, a First-in-Class Transferrin Targeted Anti-Cancer Agent to be Presented at Upcoming American Society of Clinical Oncology Annual Meeting Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL.

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy